Bayer and Recursion Pharmaceuticals have restructured and expanded their collaboration, focusing on artificial intelligence (AI)-powered drug discovery with a newfound emphasis on cancer. The revised deal, potentially valued at $1.5 billion, will see the two companies engage in up to seven precision oncology projects. Bayer’s strategic move involves leveraging Recursion’s innovative drug discovery platform, integrating ... Read more